LENZ Therapeutics IncNASDAQ:LENZ
- LAST PRICE34.3200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots32.8100/ 1
- Ask / Lots38.0000/ 4
- Open / Previous Close--- / 34.3200
- Day Range---
- 52 Week Range
- Volume303
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LENZ |
|---|---|---|
| 09:32 ET | 956 | 34 |
| 09:42 ET | 2271 | 34.045 |
| 09:44 ET | 1846 | 33.61 |
| 09:46 ET | 300 | 34 |
| 09:50 ET | 100 | 34.04 |
| 09:51 ET | 100 | 33.76 |
| 09:57 ET | 485 | 33.935 |
| 10:06 ET | 124 | 33.46 |
| 10:15 ET | 276 | 33.39 |
| 10:20 ET | 100 | 33.34 |
| 10:24 ET | 500 | 33.48 |
| 10:27 ET | 300 | 33.61 |
| 10:40 ET | 9159 | 33.82 |
| 10:47 ET | 100 | 33.89 |
| 11:02 ET | 100 | 33.81 |
| 11:03 ET | 100 | 33.705 |
| 11:16 ET | 2442 | 33.53 |
| 11:18 ET | 465 | 34.1 |
| 11:20 ET | 161 | 34.17 |
| 11:21 ET | 100 | 34 |
| 11:23 ET | 300 | 34.1 |
| 11:25 ET | 200 | 34.17 |
| 11:38 ET | 600 | 34.5 |
| 11:39 ET | 200 | 34.53 |
| 11:57 ET | 900 | 34.4 |
| 12:14 ET | 108 | 34.3574 |
| 12:33 ET | 100 | 34.4 |
| 12:35 ET | 100 | 34.365 |
| 12:39 ET | 100 | 34.48 |
| 12:55 ET | 924 | 34.56 |
| 01:11 ET | 250 | 34.5 |
| 01:51 ET | 1400 | 34.36 |
| 01:54 ET | 100 | 34.075 |
| 01:58 ET | 100 | 34.165 |
| 02:05 ET | 200 | 34.06 |
| 02:07 ET | 100 | 34 |
| 02:12 ET | 1986 | 34.04 |
| 02:16 ET | 100 | 34.035 |
| 02:18 ET | 100 | 34.2 |
| 02:20 ET | 2700 | 34.025 |
| 02:25 ET | 840 | 34.23 |
| 02:38 ET | 500 | 34.4 |
| 02:39 ET | 100 | 34.385 |
| 02:45 ET | 200 | 34.38 |
| 02:50 ET | 100 | 34.2 |
| 02:52 ET | 200 | 34.19 |
| 02:54 ET | 128 | 34.231 |
| 02:56 ET | 300 | 34.13 |
| 03:01 ET | 100 | 34.19 |
| 03:10 ET | 100 | 34.26 |
| 03:15 ET | 200 | 34.29 |
| 03:19 ET | 300 | 34.385 |
| 03:28 ET | 200 | 34.57 |
| 03:30 ET | 168 | 34.61 |
| 03:32 ET | 200 | 34.45 |
| 03:35 ET | 1300 | 34.59 |
| 03:37 ET | 718 | 34.53 |
| 03:39 ET | 100 | 34.575 |
| 03:42 ET | 100 | 34.62 |
| 03:44 ET | 100 | 34.57 |
| 03:50 ET | 1056 | 34.38 |
| 03:51 ET | 400 | 34.135 |
| 03:53 ET | 900 | 34.42 |
| 03:55 ET | 100 | 34.32 |
| 03:57 ET | 100 | 34.26 |
| 04:00 ET | 12517 | 34.32 |
Nov 12, 2024
LENZ Therapeutics to Participate in Upcoming Investor Conferences, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ LENZ Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co., from 3:27PM ET on Thursday Nov 07, 2024 by Dow Jones
3:27PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Press Release: LENZ Therapeutics Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 06, 2024 by Dow JonesLENZ Therapeutics Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 30, 2024
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024, from 8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LENZ Therapeutics Inc | 943.8M | -4.8x | --- |
Upstream Bio Inc | 954.0M | 0.0x | --- |
Septerna Inc | 915.2M | -87,160.0x | --- |
Nuvation Bio Inc | 908.7M | -1.2x | --- |
Cogent Biosciences Inc | 982.9M | -3.6x | --- |
89Bio Inc | 985.3M | -2.9x | --- |
Company Information
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Contact Information
- Headquarters
- 445 Marine View Ave Suite 320DEL MAR, CA, United States 92014
- Phone
- 858-925-7000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Perry Karsen
- President, Chief Executive Officer, Director
- Eef Schimmelpennink
- Director
- Matthew Porteus
- Independent Director
- Abraham Bassan
- Independent Director
- Jerel Davis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $943.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.54 |
EPS | $-7.08 |
Book Value | $22.15 |
P/E Ratio | -4.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
